Wells Fargo Downgrades Protalix (PLX) to Market Perform

Article Stock Quotes (1) Comments (0)

Wells Fargo's Brian Abrahams downgraded shares of Protalix BioTherapeutics (NYSE: PLX) from Outperform to Market Perform Monday morning. The analyst's valuation range was lowered from $9-$11 to $6-$8.

Abrahams lowered his likelihood of European approval for the company's Elelyso to 30 percent following the CHMP's decision not to recommend approval of the candidate "despite its favorable clinical benefit..."

For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
• Goldman Sachs Downgrades Deere (DE) to Sell, Sees 5% Downside
• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'

Create E-mail Alert Related Categories

Downgrades

Related Entities

Wells Fargo

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?